US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
DK0909323T3
(da)
|
1996-01-04 |
2007-05-21 |
Novartis Vaccines & Diagnostic |
Helicobacter pylori-bakterioferritin
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
WO1999061056A2
(en)
|
1998-05-22 |
1999-12-02 |
Loeb Health Research Institute At The Ottawa Hospital |
Methods and products for inducing mucosal immunity
|
PL201482B1
(pl)
*
|
1998-10-16 |
2009-04-30 |
Smithkline Beecham Biolog |
Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
|
US20020061848A1
(en)
*
|
2000-07-20 |
2002-05-23 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
EP1198249B1
(en)
*
|
1999-06-29 |
2005-10-19 |
GlaxoSmithKline Biologicals S.A. |
Use of cpg as an adjuvant for hiv vaccine
|
US20050002958A1
(en)
*
|
1999-06-29 |
2005-01-06 |
Smithkline Beecham Biologicals Sa |
Vaccines
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
GB9921146D0
(en)
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
GB0025170D0
(en)
*
|
2000-10-13 |
2000-11-29 |
Smithkline Beecham Biolog |
Novel compounds
|
EP1671981A3
(en)
|
2000-10-27 |
2006-07-05 |
Chiron SRL. |
Nucleic acids and proteins from streptococcus group A
|
AU2002227365A1
(en)
|
2000-12-07 |
2002-06-18 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
US7306806B2
(en)
|
2001-01-26 |
2007-12-11 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant P. falciparum merozoite protein-142 vaccine
|
AU2002248392A1
(en)
*
|
2001-01-26 |
2002-08-06 |
Walter Reed Army Institute Of Research |
Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
CN1636015A
(zh)
|
2001-06-29 |
2005-07-06 |
希龙公司 |
Hcv e1e2疫苗组合物
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
WO2003070909A2
(en)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
GB0206360D0
(en)
|
2002-03-18 |
2002-05-01 |
Glaxosmithkline Biolog Sa |
Viral antigens
|
ATE545651T1
(de)
|
2002-06-13 |
2012-03-15 |
Novartis Vaccines & Diagnostic |
Vektoren zur expression von hml-2-polypeptiden
|
EP1523557A2
(en)
|
2002-07-24 |
2005-04-20 |
Intercell AG |
Antigens encoded by alternative reading frame from pathogenic viruses
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
CA2484339A1
(en)
|
2002-09-13 |
2004-03-25 |
Intercell Ag |
Method for isolating hepatitis c virus peptides
|
MXPA05003863A
(es)
|
2002-10-11 |
2005-09-08 |
Chiron Srl |
Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
|
CA2506318C
(en)
|
2002-11-15 |
2011-07-12 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
AU2003300919A1
(en)
|
2002-12-11 |
2004-06-30 |
Coley Pharmaceutical Gmbh |
5' cpg nucleic acids and methods of use
|
US7858098B2
(en)
|
2002-12-20 |
2010-12-28 |
Glaxosmithkline Biologicals, S.A. |
Vaccine
|
CA2511512C
(en)
|
2002-12-27 |
2013-10-29 |
Chiron Corporation |
Immunogenic compositions containing phospholipid
|
KR100692203B1
(ko)
*
|
2003-01-23 |
2007-03-09 |
제일모직주식회사 |
도광판, 이의 제조 방법, 이를 이용한 백라이트 어셈블리및 이를 이용한 액정표시장치
|
CN102302776B
(zh)
|
2003-01-30 |
2014-06-18 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
WO2004084938A1
(en)
|
2003-03-24 |
2004-10-07 |
Intercell Ag |
Improved vaccines
|
ES2351489T3
(es)
*
|
2003-03-24 |
2011-02-07 |
Intercell Ag |
Vacunas mejoradas.
|
ES2423800T3
(es)
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos orgánicos para la inmunopotenciación
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
FR2854803B1
(fr)
*
|
2003-05-16 |
2005-06-24 |
Aventis Pasteur |
Composition vaccinale comprenant du phosphate de fer a titre d'adjuvent vaccinal.
|
PL1631264T5
(pl)
|
2003-06-02 |
2018-09-28 |
Glaxosmithkline Biologicals Sa |
Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
|
PL1648500T3
(pl)
|
2003-07-31 |
2014-12-31 |
Novartis Vaccines & Diagnostics Inc |
Kompozycje immunogenne dla Streptococcus pyogenes
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
WO2005107797A1
(en)
|
2004-03-09 |
2005-11-17 |
Chiron Corporation |
Influenza virus vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
BRPI0510315A
(pt)
|
2004-04-30 |
2007-10-16 |
Chiron Srl |
integração de vacinação com conjugado meningocócico
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2848692B1
(en)
|
2004-05-21 |
2017-08-16 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
US7758866B2
(en)
|
2004-06-16 |
2010-07-20 |
Glaxosmithkline Biologicals, S.A. |
Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
|
CA2571421A1
(en)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Compounds for immunopotentiation
|
EP2612679A1
(en)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
PT2682126T
(pt)
|
2005-01-27 |
2017-02-28 |
Children`S Hospital & Res Center At Oakland |
Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
EP1850871A2
(en)
*
|
2005-02-16 |
2007-11-07 |
Novartis Vaccines and Diagnostics, Inc. |
Adjuvant composition comprising aluminium phosphate and 3d-mpl
|
CA2601924A1
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
WO2006091517A2
(en)
|
2005-02-18 |
2006-08-31 |
Novartis Vaccines And Diagnostics Inc. |
Immunogens from uropathogenic escherichia coli
|
ATE526036T1
(de)
*
|
2005-08-02 |
2011-10-15 |
Novartis Vaccines & Diagnostic |
Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
WO2007052055A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
AU2006310246B2
(en)
*
|
2005-11-04 |
2010-12-23 |
Seqirus UK Limited |
Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
JP5539649B2
(ja)
|
2005-12-13 |
2014-07-02 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
細胞移植のための足場
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
MY150719A
(en)
|
2005-12-22 |
2014-02-28 |
Glaxosmithkline Biolog Sa |
Pneumococcal polysaccharide conjugate vaccine
|
KR20080089663A
(ko)
|
2006-01-27 |
2008-10-07 |
노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 |
적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
|
ES2376492T3
(es)
|
2006-03-23 |
2012-03-14 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores.
|
WO2007110776A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
KR101541383B1
(ko)
|
2006-03-30 |
2015-08-03 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
면역원성 조성물
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
CN1864749B
(zh)
*
|
2006-04-12 |
2010-10-06 |
成都夸常医学工业有限公司 |
一种药物组合物及制备方法
|
US9839685B2
(en)
*
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
MX2008016280A
(es)
|
2006-06-29 |
2009-03-26 |
Novartis Ag |
Polipeptidos a partir de neisseria meningitidis.
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
EP2497495B3
(en)
|
2006-09-11 |
2021-02-17 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8080645B2
(en)
*
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
JP5443164B2
(ja)
|
2006-09-26 |
2014-03-19 |
インフェクティアス ディジーズ リサーチ インスティチュート |
合成アジュバントを含むワクチン組成物
|
ES2480491T3
(es)
|
2006-12-06 |
2014-07-28 |
Novartis Ag |
Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
US9610340B2
(en)
|
2007-06-26 |
2017-04-04 |
Glaxosmithkline Biologicals, S.A. |
Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
|
WO2009001217A2
(en)
|
2007-06-27 |
2008-12-31 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
EP3058954B1
(en)
|
2007-08-27 |
2017-03-01 |
Longhorn Vaccines and Diagnostics, LLC |
Immunogenic compositions and methods
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
EP2535428B1
(en)
|
2007-10-01 |
2015-09-09 |
Longhorn Vaccines and Diagnostics, LLC |
Biological specimen collection and transport system and methods of use
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN104292312A
(zh)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
RS55162B1
(sr)
*
|
2007-12-24 |
2017-01-31 |
Id Biomedical Corp Quebec |
Rekombinantni rsv antigeni
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
WO2009114485A2
(en)
|
2008-03-10 |
2009-09-17 |
Children's Hospital & Research Center At Oakland |
Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
|
US20110014230A1
(en)
|
2008-03-18 |
2011-01-20 |
Novartis Ag |
preparation of influenza virus vaccine antigens
|
CA2826508C
(en)
|
2008-05-23 |
2016-07-19 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
CA2722847C
(en)
*
|
2008-05-26 |
2019-12-17 |
Cadila Healthcare Limited |
Combined measles-human papilloma vaccine
|
US9114098B2
(en)
|
2008-06-04 |
2015-08-25 |
The Chemo-Sero-Therapeutic Research Institute |
Method for using inactivated Japanese encephalitis virus particles as adjuvant
|
WO2010006447A1
(en)
*
|
2008-07-18 |
2010-01-21 |
Id Biomedical Corporation Of Quebec |
Chimeric respiratory syncytial virus polypeptide antigens
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
EP2865389A1
(en)
|
2008-12-09 |
2015-04-29 |
Pfizer Vaccines LLC |
IgE CH3 peptide vaccine
|
CA2751379C
(en)
|
2009-02-10 |
2018-06-12 |
Novartis Ag |
Influenza vaccines with reduced amounts of squalene
|
NZ700477A
(en)
*
|
2009-02-17 |
2016-04-29 |
Glaxosmithkline Biolog Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
AU2010220824A1
(en)
*
|
2009-03-05 |
2011-10-20 |
Jenny Colleen Mccloskey |
Treatment of infection
|
CN102438650A
(zh)
|
2009-03-06 |
2012-05-02 |
诺华有限公司 |
衣原体抗原
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
WO2010131111A1
(en)
|
2009-05-11 |
2010-11-18 |
Novartis Ag |
Antigen purification process for pertactin antigen
|
DK2437753T3
(en)
|
2009-06-05 |
2016-12-19 |
Infectious Disease Res Inst |
Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
|
JP5551774B2
(ja)
|
2009-06-15 |
2014-07-16 |
ナショナル ユニヴァーシティー オブ シンガポール |
インフルエンザワクチン、組成物、および使用方法
|
JP6110140B2
(ja)
*
|
2009-06-16 |
2017-04-05 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
ナノエマルションワクチン
|
PE20121541A1
(es)
|
2009-06-24 |
2012-12-21 |
Glaxosmithkline Biolog Sa |
Antigenos de virus de sincicio respiratorio recombinantes
|
CA2766205A1
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine comprising at least two paramyxovirus f protein antigens
|
SG177269A1
(en)
|
2009-06-25 |
2012-02-28 |
Glaxosmithkline Biolog Sa |
Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
|
MX2012000395A
(es)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Inmunogenos conservados de escherichia coli.
|
EP4218799A1
(en)
|
2009-07-15 |
2023-08-02 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
KR20120049900A
(ko)
|
2009-07-30 |
2012-05-17 |
화이자 백신스 엘엘씨 |
항원성 타우 펩타이드 및 이의 용도
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
JP5933437B2
(ja)
*
|
2009-08-26 |
2016-06-08 |
セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. |
T細胞ヘルプを誘発する組成物
|
NZ622048A
(en)
|
2009-08-27 |
2015-10-30 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
CN102612558B
(zh)
|
2009-09-03 |
2015-02-11 |
辉瑞疫苗有限责任公司 |
Pcsk9疫苗
|
MX338753B
(es)
|
2009-09-30 |
2016-04-29 |
Novartis Ag |
Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
WO2011051893A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
KR20120120185A
(ko)
|
2009-12-22 |
2012-11-01 |
셀덱스 쎄라퓨틱스, 인크. |
백신 조성물
|
SG182573A1
(en)
|
2010-01-27 |
2012-08-30 |
Glaxosmithkline Biolog Sa |
Modified tuberculosis antigens
|
EP4036104B1
(en)
|
2010-03-30 |
2024-02-21 |
Children's Hospital & Research Center at Oakland |
Factor h binding proteins (fhbp) with altered properties and methods of use thereof
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
EP2582393A4
(en)
|
2010-05-26 |
2014-04-02 |
Selecta Biosciences Inc |
DOSE SELECTION OF SYNTHETIC NANOVECTORS WITH ADJUVANT
|
EP2575988A1
(en)
|
2010-05-28 |
2013-04-10 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
WO2011148382A1
(en)
|
2010-05-28 |
2011-12-01 |
Biological E Limited |
An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
|
EP2575868A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
US8895017B2
(en)
|
2010-06-07 |
2014-11-25 |
Pfizer Inc. |
HER-2 peptides and vaccines
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
MX2013000163A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Metodos y composiciones inmunogenicas derivadas de norovirus.
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
CN102441162B
(zh)
*
|
2010-10-04 |
2018-07-24 |
免疫产品美国股份有限公司 |
结核病的治疗和预防
|
EA201390660A1
(ru)
|
2010-11-05 |
2013-11-29 |
Селекта Байосайенсиз, Инк. |
Модифицированные никотиновые соединения и связанные способы
|
CA2860331A1
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
EP2667892B1
(en)
|
2011-01-26 |
2019-03-27 |
GlaxoSmithKline Biologicals SA |
Rsv immunization regimen
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
JP5798356B2
(ja)
*
|
2011-04-06 |
2015-10-21 |
一般財団法人化学及血清療法研究所 |
新規インフルエンザワクチン安定化剤
|
EP3632463A1
(en)
|
2011-04-08 |
2020-04-08 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
PT2707385T
(pt)
|
2011-05-13 |
2017-12-19 |
Glaxosmithkline Biologicals Sa |
Antigénios de f de rsv pré-fusão
|
EP2726097A4
(en)
*
|
2011-07-01 |
2015-03-11 |
Univ California |
HERPES VIRUS VACCINE AND METHOD OF USE
|
EP3332802A1
(en)
|
2011-07-06 |
2018-06-13 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
FR2977800B1
(fr)
*
|
2011-07-13 |
2014-03-14 |
Sanofi Pasteur |
Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
|
US20130039954A1
(en)
|
2011-07-29 |
2013-02-14 |
Selecta Biosciences, Inc. |
Control of antibody responses to synthetic nanocarriers
|
EP3329936A1
(en)
|
2011-08-22 |
2018-06-06 |
Nanobio Corporation |
Herpes simplex virus nanoemulsion vaccine
|
CN104093421A
(zh)
|
2011-09-09 |
2014-10-08 |
纳诺碧欧公司 |
纳米乳液呼吸道合胞病毒(rsv)亚单位疫苗
|
US20150190501A1
(en)
|
2011-09-12 |
2015-07-09 |
Imperial Innovations Limited |
Methods and compositions for raising an immune response to hiv
|
JP2015500864A
(ja)
|
2011-12-23 |
2015-01-08 |
ノバルティス アーゲー |
黄色ブドウ球菌(Staphylococcusaureus)に対して免疫するための安定な組成物
|
CN104203272A
(zh)
|
2012-01-26 |
2014-12-10 |
长角牛疫苗和诊断有限责任公司 |
复合抗原序列及疫苗
|
US20150110824A1
(en)
|
2012-03-18 |
2015-04-23 |
Glaxosmithkline Biologicals, Sa |
Method of vaccination against human papillomavirus
|
JP6199957B2
(ja)
*
|
2012-04-16 |
2017-09-20 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
免疫応答を調節するためのメソポーラスシリカ組成物
|
EP2659906A1
(en)
*
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
*
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
NZ701881A
(en)
|
2012-05-16 |
2016-10-28 |
Immune Design Corp |
Vaccines for hsv-2
|
AU2013265336A1
(en)
|
2012-05-22 |
2014-12-04 |
Novartis Ag |
Meningococcus serogroup X conjugate
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
US20150203543A1
(en)
|
2012-08-31 |
2015-07-23 |
Novartis Ag |
Stabilised proteins for immunising against staphylococcus aureus
|
TR201910573T4
(tr)
|
2012-08-31 |
2019-08-21 |
Glaxosmithkline Biologicals Sa |
Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
|
MX2015004171A
(es)
|
2012-10-02 |
2015-10-22 |
Glaxosmithkline Biolog Sa |
Conjugados de sacaridos no lineales.
|
ES2773954T3
(es)
|
2012-10-03 |
2020-07-15 |
Glaxosmithkline Biologicals Sa |
Composición inmunogénica
|
EP2908857B1
(en)
*
|
2012-10-19 |
2017-08-09 |
Hal Allergy Holding B.V. |
Compositions for immunotherapy
|
ES2656510T3
(es)
|
2012-11-30 |
2018-02-27 |
Glaxosmithkline Biologicals S.A. |
Antígenos de Pseudomonas y combinación de antigenos
|
US8957047B2
(en)
|
2013-04-18 |
2015-02-17 |
Immune Design Corp. |
GLA monotherapy for use in cancer treatment
|
CN112999344A
(zh)
|
2013-05-15 |
2021-06-22 |
阿尔伯达大学董事会 |
E1e2 hcv疫苗及使用方法
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
US9492559B2
(en)
|
2014-01-21 |
2016-11-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
ES2769647T3
(es)
|
2014-03-26 |
2020-06-26 |
Glaxosmithkline Biologicals Sa |
Antígenos estafilocócicos mutantes
|
EP3137105A4
(en)
|
2014-04-30 |
2017-12-27 |
President and Fellows of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
BR112017001417B1
(pt)
|
2014-07-23 |
2023-11-07 |
Children's Hospital & Research Center At Oakland |
Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
|
HRP20230416T1
(hr)
|
2015-01-15 |
2023-07-07 |
Pfizer Inc. |
Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
|
US11786457B2
(en)
|
2015-01-30 |
2023-10-17 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
WO2016183292A1
(en)
|
2015-05-14 |
2016-11-17 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
EP3302536A1
(en)
|
2015-06-03 |
2018-04-11 |
Affiris AG |
Il-23-p19 vaccines
|
AU2016289497A1
(en)
|
2015-07-07 |
2017-12-07 |
Affiris Ag |
Vaccines for the treatment and prevention of IgE mediated diseases
|
KR102225282B1
(ko)
|
2015-07-21 |
2021-03-10 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
EP3411475A4
(en)
|
2016-02-06 |
2019-09-11 |
President and Fellows of Harvard College |
REGENERATION OF THE HEMATOPOIETIC NICHE TO RECONSTITUTE IMMUNITY
|
CN109789092A
(zh)
|
2016-07-13 |
2019-05-21 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
US11466292B2
(en)
|
2016-09-29 |
2022-10-11 |
Glaxosmithkline Biologicals Sa |
Compositions and methods of treatment
|
KR102028463B1
(ko)
|
2016-11-25 |
2019-10-04 |
재단법인 목암생명과학연구소 |
바리셀라 조스터 바이러스 백신
|
WO2018097642A1
(ko)
*
|
2016-11-25 |
2018-05-31 |
재단법인 목암생명과학연구소 |
바리셀라 조스터 바이러스 백신
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
CN107537035A
(zh)
*
|
2017-08-30 |
2018-01-05 |
北京恩元华生物科技有限公司 |
复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
WO2019175145A1
(en)
|
2018-03-12 |
2019-09-19 |
Janssen Vaccines & Prevention B.V. |
Vaccines against urinary tract infections
|
CA3102224A1
(en)
|
2018-06-12 |
2019-12-19 |
Glaxosmithkline Biologicals Sa |
Chimpanzee adenovirus chad157 polynucleotides, polypeptides.vectors, compositions, cells and uses thereof
|
US20210283238A1
(en)
|
2018-08-07 |
2021-09-16 |
Glaxosmithkline Biologicals Sa |
Novel processes and vaccines
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
MX2021005303A
(es)
|
2018-11-06 |
2021-07-07 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogenicas.
|
US20220016229A1
(en)
|
2018-12-12 |
2022-01-20 |
Pfizer Inc. |
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CN113573730A
(zh)
|
2019-03-05 |
2021-10-29 |
葛兰素史密斯克莱生物公司 |
乙型肝炎免疫方案和组合物
|
JOP20210256A1
(ar)
|
2019-03-18 |
2023-01-30 |
Janssen Pharmaceuticals Inc |
متقارن حيوي لعديدات سكاريد المستضدات-o للإشريكية القولونية، طرائق إنتاجه، وطرائق استخدامه
|
AR118389A1
(es)
|
2019-03-18 |
2021-09-29 |
Janssen Pharmaceuticals Inc |
Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CN112138155B
(zh)
*
|
2019-06-28 |
2022-04-12 |
怡道生物科技(苏州)有限公司 |
一种复合佐剂***及制备该佐剂的方法
|
CN115151559A
(zh)
|
2019-10-02 |
2022-10-04 |
扬森疫苗与预防公司 |
葡萄球菌肽和使用方法
|
WO2021084429A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2021144369A1
(en)
|
2020-01-16 |
2021-07-22 |
Janssen Pharmaceuticals, Inc. |
Fimh mutant, compositions therewith and use thereof
|
WO2021151100A1
(en)
|
2020-01-24 |
2021-07-29 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
CN115362177A
(zh)
|
2020-02-21 |
2022-11-18 |
辉瑞公司 |
糖类的纯化
|
IL295632A
(en)
|
2020-02-23 |
2022-10-01 |
Pfizer |
Escherichia coli preparations and their methods
|
JP2023514825A
(ja)
|
2020-02-26 |
2023-04-11 |
ヴェルシテック リミテッド |
コロナウイルス感染症に対するpd-1ベースのワクチン
|
CN111920946B
(zh)
*
|
2020-08-07 |
2021-05-28 |
合肥诺为尔基因科技服务有限公司 |
环二核苷酸修饰铝纳米粒疫苗佐剂-传递***及基于其的SARS-CoV-2亚单位疫苗
|
EP4213870A1
(en)
|
2020-09-17 |
2023-07-26 |
Janssen Pharmaceuticals, Inc. |
Multivalent vaccine compositions and uses thereof
|
WO2022090893A2
(en)
|
2020-10-27 |
2022-05-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2022097010A1
(en)
|
2020-11-04 |
2022-05-12 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
EP4243863A2
(en)
|
2020-11-10 |
2023-09-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
MX2023008251A
(es)
|
2021-01-12 |
2023-07-26 |
Janssen Pharmaceuticals Inc |
Mutantes de fimh, composiciones con estos y uso de estos.
|
EP4291231A1
(en)
|
2021-02-11 |
2023-12-20 |
GlaxoSmithKline Biologicals S.A. |
Hpv vaccine manufacture
|
IT202100003470A1
(it)
|
2021-02-16 |
2022-08-16 |
Fond Toscana Life Sciences |
Vaccines against sars-cov-2
|
IL305313A
(en)
|
2021-02-19 |
2023-10-01 |
Sanofi Pasteur |
Recombinant meningococcal B vaccine
|
CN115120713A
(zh)
*
|
2021-03-25 |
2022-09-30 |
四川大学 |
氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途
|
MX2023011697A
(es)
|
2021-04-01 |
2023-10-19 |
Janssen Pharmaceuticals Inc |
Produccion de bioconjugados o18 de e. coli.
|
EP4333868A1
(en)
|
2021-05-04 |
2024-03-13 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
MX2023013434A
(es)
|
2021-05-28 |
2023-12-12 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
|
JP2024521847A
(ja)
|
2021-05-28 |
2024-06-04 |
ファイザー・インク |
コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|